CABALETTA BIO, INC. Finance Lease, Liability, to be Paid, Remainder of Fiscal Year
CABALETTA BIO, INC. (CABA) had Finance Lease, Liability, to be Paid, Remainder of Fiscal Year of $9.47 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear · last filed 2026-08-13
- 2026-06-30: Finance Lease, Liability, to be Paid, Remainder of Fiscal Year $9.47M.
- 2026-03-31: Finance Lease, Liability, to be Paid, Remainder of Fiscal Year $17.57M.
- 2025-09-30: Finance Lease, Liability, to be Paid, Remainder of Fiscal Year $6.35M.
- 2025-06-30: Finance Lease, Liability, to be Paid, Remainder of Fiscal Year $8.23M.
| Period end | Finance Lease, Liability, to be Paid, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $9.47M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $17.57M 10-Q · filed 2026-05-14 |
| 2025-09-30 | $6.35M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $8.23M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $11.43M 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |